window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : June 6, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Central Nervous System

  • Central Nervous System,Clinical & Regulatory,Drug Delivery & Formulation,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Positive Phase 3 KALOS and LOGOS trial results for Breztri published in The Lancet Respiratory Medicine

    Full results from the Phase 3 KALOS and LOGOS trials [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Newron publishes data showing clinically meaningful benefits of evenamide in treatment-resistant schizophrenia

    Newron Pharmaceuticals has published peer-reviewed clinical data demonstrating that evenamide, [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Therapeutic Areas

    Rainwater Charitable Foundation announces 2026 Rainwater Prize winners for tauopathy research

    The Rainwater Charitable Foundation (RCF) has announced the recipients of [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Skyhawk Therapeutics reports positive nine-month interim results for SKY-0515 in Huntington’s disease

    Skyhawk Therapeutics has reported positive nine-month interim results from its [...]

    May 5, 2026
  • Central Nervous System,Digital & Data,Medical devices,Opinion & Events,Pharmaceuticals and therapeutics

    NeuroVice seizure oral injury device now available through BlinkRx

    The PATI device from NeuroVice, designed to protect against oral [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Accord Healthcare disappointed as people with ES-SCLC in Scotland denied access to serplulimab

    Patients in Scotland living with extensive-stage small cell lung cancer [...]

    May 5, 2026
  • Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Exciva raises €51 million Series B to fund phase 2 Alzheimer’s agitation trial

    Exciva GmbH has raised €51 million ($59m) in a Series [...]

    May 5, 2026
  • Biotech & Pharma Business,Central Nervous System,Therapeutic Areas

    AstronauTx appoints Adam Rosenberg as Chair of the Board

    AstronauTx has appointed Adam Rosenberg as chair of the board, [...]

    May 5, 2026
  • Central Nervous System,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Neuraxpharm expands ADHD treatment options in Europe with Tuzulby and Paxneury launches

    Neuraxpharm has launched two new treatments for attention deficit hyperactivity [...]

    May 5, 2026
  • Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory

    Single-cell analysis highlights molecular subgroups in endometriosis that could inform clinical trials

    Endometriosis is typically treated as a single condition, yet patients [...]

    May 5, 2026
Previous123Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Quotient Sciences begins Phase 1 study of AI-designed drug formulation
    Categories: Clinical & Regulatory, Digital & Data, Drug Discovery & Development, Pharmaceuticals and therapeutics
  • Baptist Health and START expand access to early-phase cancer trials in South Florida
    Categories: Clinical & Regulatory, Therapeutic Areas
  • Countable Labs raises $26m to expand Countable PCR platform
    Categories: Clinical & Regulatory, Digital & Data, Drug Discovery & Development, Genomics and sequencing
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top